



---

**FOR IMMEDIATE RELEASE**

**Lee's Pharma Announced the New Drug Registration of Natulan®  
for Hodgkin's Disease in China**

**Hong Kong, May 3, 2011**—Lee's Pharmaceutical Holdings Limited (Main Broad Stock: 0950: Website: [www.leespharm.com](http://www.leespharm.com)) today announced that the Group has successfully submitted application of the New Drug Registration in China for Sigma-Tau's product, **Natulan®** (Procarbazine Hydrochloride Capsule), for the treatment of Hodgkin's disease and non-Hodgkin's lymphoma.

The application was submitted with the fast-track designation. As Natulan® targets rare disease with unmet medical need, a waiver of registration clinical study is sought in the application in accordance with the relevant registration regulation.

"We're extremely excited about this project. This is our first filing of an orphan drug in China and will be one of the several ones that follow. It is the Group's intention to build an orphan drug portfolio to serve the under served patients in China. We are dedicated to the orphan disease area in China and more filing is expected in the near future", said Dr. Benjamin Li, the Chief Executive Officer of the Company.

Natulan® (procarbazine) in combination chemotherapy is suitable for the treatment of Hodgkin's lymphoma and certain brain cancers (such as glioblastoma multiforme). It is a member of a group of medicines called alkylating agents. It has originally been developed by Hoffmann-La Roche, which first filed a patent claiming its preparation process and its use. The drug (Matulane®) gained FDA approval in the US in July 1969.

**About Hodgkin's Disease**

Hodgkin's lymphoma — formerly known as Hodgkin's disease — is a cancer of the lymphatic system, which is part of your immune system. In Hodgkin's lymphoma, cells in the lymphatic system grow abnormally and may spread beyond the lymphatic system. As Hodgkin's lymphoma progresses, it compromises your body's ability to fight infection. Hodgkin's Lymphoma can affect the lymph nodes, spleen, bone marrow, and other internal organs. Hodgkin's lymphoma is one of two common types of cancers of the lymphatic system. The other type, non-Hodgkin's lymphoma, is far more common.

---

**FOR IMMEDIATE RELEASE**

**About Sigma-Tau**

**Sigma-Tau** is one of the most important Italian pharmaceutical groups, which, with an excellent role internationally and a workforce of 2,439 achieved a corporate turnover of about €615 million in 2009. The Sigma-Tau complex in Pomezia, the site of the Group's head office, houses not only the main factory, but also Avantgarde, a company operating in the pharmaceutical field and specializing in dermatology and gynaecology. Ever since its foundation in 1957, sigma-tau has based the various stages of its development on a single common denominator: research. The company's primacy in this field is an indispensable part of its corporate philosophy. A tangible impact on the quality of life can only be attained through constant, top-level research. Sigma-tau employs about 400 researchers, providing them with the means and resources to develop the therapeutic breakthroughs needed to guarantee better health conditions for everyone. For further information about Sigma-Tau: Website: [www.sigma-tau.it](http://www.sigma-tau.it)

**About Lee's Pharmaceutical**

Lee's Pharmaceutical Holdings Limited is a public biopharmaceutical company with over 16 years operation in China's pharmaceutical industry. It is fully integrated with solid infrastructures in drug development, clinical development, regulatory, manufacturing, sales and marketing in China with global perspectives and currently markets nine products. Leespharm focuses on several key therapeutic areas such as cardiovascular and infectious diseases, dermatology, oncology, gynecology. It has more than 30 products under different development stages stemming from both internal R&D as well as from the recent acquisition of licensing and distribution rights from 18 US, European and Japanese companies. The mission of Lee's is to become a successful biopharmaceutical group in Asia providing innovative products to fight diseases and improve health and quality of life. For further information about Lee's Pharmaceutical: Website: [www.leespharm.com](http://www.leespharm.com)

**Safe Harbor Statement**

*The statements in this news release, other than the historical financial information, may contain forward-looking statements that involve risks and uncertainties that could cause actual results to differ from anticipated results. Further information on risk factor that could affect, among other things, Lee's financial condition and results of operations is detailed in Lee's IPO prospectus, as filed with the Main Board of the Stock Exchange of Hong Kong Limited.*

*For further information, please contact:  
Vivian Fung  
Tel: (852)2314-1282*



---

**FOR IMMEDIATE RELEASE**

*Fax: (852)2314-1708*

*Email: [info@leespharm.com](mailto:info@leespharm.com)*